Shattuck Labs, Inc. (STTK) research
Shattuck Labs, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.31
- As of
Shattuck Labs, Inc. (STTK): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
As of . Source: SEC EDGAR filings for STTK. Method and limitations.
Share the STTK intelligence card
See STTK live in the terminal
Track STTK's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live STTK terminal, freeActive signals for STTK
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 75% of STTK (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 75% of STTK (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 75% of STTK (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 75% of STTK (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +60% to STTK (2026Q1)
FREE, NO ACCOUNT
Every signal on STTK, as it fires
You are seeing 5 of 9 signals recorded on STTK since 2026-05-24.
The five above landed across 3 days. The other 4 were recorded on 1 other days. 6 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in STTK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 82024L103 · 2026Q2 | $8.1M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 82024L103 · 2026Q2 | $5.2M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 82024L103 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 82024L103 · 2026Q2 | $1.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, STTK
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
STTK against its peers
STTK's operating margin of -5150.8% ranks in the 12th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | STTK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.0M USD | 7.3M USD | 41 | 15 |
| Operating margin | -5150.8% | -94.6% | 13 | 11 |
| Net margin | -4880.9% | -126.3% | 13 | 11 |
| Return on equity | -59.2% | -45.8% | 38 | 19 |
Peers (20): CRMD, ALLO, VALN, PHAT, CBIO, ALT, CTMX, EPRX, NGNE, PRME, OCS, MNPR, AURA, VSTM, ARVN, RGNX, TECX, SGMT, CAPR, OVID. Left out: SCTX (no annual filing), AGMB (no annual filing), DRUG (period gap), EIKN (no annual filing), BLSM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (STTK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more STTK signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to STTKand get the insider, 13F, options, and confluence read in one view.